2 articles in this category
Negative free cash flow and high debt are offset by strong upcoming catalysts and recent positive trial data, pointing to near-term upside.
Strong analyst momentum and positive Phase 1 weight-loss data outweigh near-term cash burn, signaling upside in WVE.